Le marché des radiopharmaceutiques devrait atteindre 13 818,17 millions de dollars US d'ici 2028, contre 7 550,74 millions de dollars US en 2021 ; il devrait croître à un TCAC de 9,0 % de 2021 à 2028.
La croissance du marché est attribuée à la prévalence croissante des maladies chroniques, à la pertinence de la radioimmunothérapie alpha dans le traitement ciblé du cancer et aux progrès de techniques d'imagerie nucléaire. Cependant, la courte durée de conservation des radiopharmaceutiques et la disponibilité de substituts freinent la croissance du marché des radiopharmaceutiques. Un radiopharmaceutique est un médicament qui peut être utilisé à des fins diagnostiques ou thérapeutiques. Les radiopharmaceutiques sont des radio-isotopes liés à des molécules biologiques qui ciblent des tissus, des organes ou des cellules spécifiques du corps humain. Les radio-isotopes émettant des rayons gamma sont utiles pour l'imagerie diagnostique où le rayonnement s'échappe du corps. Ces rayons sont détectés par un appareil spécifique, qui est généralement des caméras de tomographie par émission monophotonique (SPECT)/tomographie par émission de positrons (TEP).
La pandémie de COVID-19 a profondément modifié les activités hospitalières, y compris les activités nucléaires. pratiques médicales (NM) à travers l'Europe. Une recherche documentaire sur PubMed a été effectuée couvrant les études COVID-19 publiées jusqu'en janvier 2021. Selon les résultats, la pandémie a fortement mis à l'épreuve les départements NM, et une réduction des effectifs a été constatée dans tous les centres en Europe. Pour limiter la transmission du COVID-19, les départements de NM ont introduit des mesures de restriction, telles que le report des procédures non prioritaires. De plus, quelques départements ont connu un retard d'approvisionnement en radiopharmaceutiques ou d'assistance technique en raison de la pandémie. En conséquence, la crise a entraîné une réduction significative des procédures diagnostiques et thérapeutiques de NM et une réduction du niveau de soins pour les patients touchés par des maladies telles que le cancer ou les maladies cardiovasculaires aiguës.
Régions lucratives pour le marché des radiopharmaceutiques < /div>
Aperçu du marché
La prévalence croissante des maladies chroniques alimente la croissance du marché des radiopharmaceutiques
La prévalence des maladies chroniques telles que les maladies cardiovasculaires (MCV), le cancer, les maladies pulmonaires chroniques, les accidents vasculaires cérébraux, la maladie d'Alzheimer, les maladies rénales chroniques et plusieurs troubles neurologiques augmentent rapidement à travers le monde. Ces maladies figurent parmi les principales causes de décès. Selon l'Organisation mondiale de la santé (OMS), le cancer a causé 10 millions de décès en 2020 dans le monde. De plus, selon les estimations de l'American Cancer Society, 1 806 590 nouveaux cas de cancer ont été diagnostiqués aux États-Unis en 2020. Selon le European Heart Network, les maladies cardiovasculaires causent 3,9 millions de décès en Europe et plus de 1,8 million de décès dans l'Union européenne ( UE) chaque année. Ils représentent 45,0 % du total des décès en Europe et 37,0 % du nombre total de décès dans l'UE. Selon l'American College of Cardiology, les maladies cardiovasculaires causent 800 000 décès aux États-Unis chaque année. Les maladies coronariennes (CHD) contribuent à la majorité des décès par MCV, suivies des accidents vasculaires cérébraux et de l'insuffisance cardiaque ; 90 millions d'Américains reçoivent un diagnostic de maladies cardiovasculaires chaque année. En outre, les maladies cardiovasculaires contribuent à 31 % du nombre total de décès dans le monde, et la charge financière des maladies cardiovasculaires sur les systèmes de santé devrait s'élever à 1 044 milliards de dollars d'ici 2030.
Selon Emory Healthcare, en 2018, 5 millions personnes souffrent d'insuffisance cardiaque congestive (ICC) aux États-Unis. De plus, selon l'OMS, environ 1,71 milliard de personnes dans le monde souffrent de troubles musculo-squelettiques. Un examen efficace est indispensable pour le traitement des maladies chroniques et les substances nucléaires sont utilisées à des fins de diagnostic et d'examen; ils sont utilisés dans des tests de diagnostic tels que la tomographie par émission de positrons (TEP) et la tomographie informatisée d'émission à photon unique (SPECT). Ainsi, avec une augmentation de l'incidence des maladies chroniques, le besoin de radiopharmaceutiques augmente également, entraînant ainsi la croissance du marché.
Insights basés sur le type
Selon le type, les radiopharmaceutiques Le marché est divisé en médecine nucléaire diagnostique et en médecine nucléaire thérapeutique. Le segment de la médecine nucléaire diagnostique détient une plus grande part du marché et devrait enregistrer un TCAC plus élevé au cours de la période 2021-2028. Le radio-isotope largement utilisé en médecine nucléaire diagnostique est le technétium-99m. Le radio-isotope se fixe sur plusieurs molécules spécifiques, permettant le diagnostic de diverses maladies, comme certains types de cancers. Par exemple, le technétium-99m-MDP (diphosphonate de méthylène) est largement utilisé pour détecter les métastases osseuses associées au cancer.
Marché des radiopharmaceutiques, par type - 2021 et 2028
Basé sur le type de produit Insights
Sur la base du type de produit, le marché des radiopharmaceutiques est segmenté en technétium-99m, thallium-201, gallium-67, iode-131, cuivre-64 et autres. Le segment du technétium-99m détient la plus grande part du marché, tandis que le segment du gallium-67 devrait enregistrer le TCAC le plus élevé au cours de la période 2021-2028. Le gallium-67 est utilisé pour l'imagerie et la localisation des lésions inflammatoires (infections). Le gallium-67 est un radiopharmaceutique injectable qui est utilisé avec la tomodensitométrie d'émission monophotonique (SPECT) pour détecter la présence de lésions inflammatoires aiguës et de diverses tumeurs malignes, telles que la maladie de Hodgkin, les lymphomes et les carcinomes bronchiques.
Aperçus basés sur les applications
Sur la base des applications, le marché des radiopharmaceutiques est segmenté en oncologie, cardiologie, neurologie et autres. Le segment de l'oncologie détient la plus grande part du marché. La croissance du marché pour ce segment peut être attribuée à l'incidence croissante du cancer dans le monde. Le cancer est l'un des problèmes de santé importants avec un taux de mortalité élevé. C'est une menace pour la santé mondiale. Selon l'OMS, en 2018, environ 18 millions de nouveaux cas de cancer ont été diagnostiqués dans le monde et 9,6 millions de personnes sont décédées du cancer. Cependant, le marché du segment de la cardiologie devrait croître au rythme le plus rapide dans les années à venir.
Insights basés sur l'utilisateur final
Basé sur l'utilisateur final, le marché des radiopharmaceutiques est segmenté dans les hôpitaux, les centres d'imagerie, les centres universitaires et de recherche, et autres. En 2021, le segment des hôpitaux détient la plus grande part du marché. La croissance du marché pour ce segment peut être attribuée à la prévalence croissante des maladies chroniques, au nombre croissant d'hôpitaux dans le monde et au nombre croissant d'interventions chirurgicales. Cependant, le marché du segment des centres de diagnostic devrait croître au rythme le plus rapide dans les années à venir.
Aperçus stratégiques
Les entreprises opérant sur le marché des radiopharmaceutiques adoptent la stratégie d'innovations de produits pour répondre à l'évolution des demandes des clients à travers le monde, ce qui leur permet également de maintenir leur marque sur le marché mondial.
Marché des radiopharmaceutiques - par type
- Médecine nucléaire diagnostique < ul>
- Produits radiopharmaceutiques SPECT
- Produits radiopharmaceutiques TEP
- Émetteurs alpha
- Bêta Émetteurs
- Isotopes de curiethérapie
Marché des radiopharmaceutiques - par type de produit
- Technétium-99m
- Thallium-201
- Gallium-67
- Iode-131
- Cuivre-64
- Autre
Marché des radiopharmaceutiques - par application
- Oncologie
- Cardiologie
- Neurologie
- Autres
Marché des radiopharmaceutiques - par utilisateur final
- Hôpitaux
- Centres d'imagerie
- Centres universitaires et de recherche
< li>Autres
Marché des radiopharmaceutiques - par géographie
- Amérique du Nord
- États-Unis
- Canada
- Mexique
- Europe
- France
- Allemagne
- Italie
- Royaume-Uni
- Espagne
- Reste de l'Europe
- Asie-Pacifique (APAC)
- Chine
- Inde
- Corée du Sud
- Japon
- Australie
- Reste de l'APAC
- Moyen-Orient et Afrique (MEA)
- Afrique du Sud
- Arabie saoudite
- EAU
- Reste du MEA
- Amérique du Sud et centrale (SCAM)
- Brésil
- Argentine
- Reste de la SCAM
Profils des entreprises
- Cardinal Health
- GE Healthcare
- Curium
- Lantheus Medical Imaging
- Bayer AG
- Bracco Imaging
- Eczacýbaþý-Monrol Nuclear Products
- Nordion
- Applications avancées des accélérateurs
- Radio-isotopes NTP
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Radiopharmaceuticals are radioisotopes that are bound to biological molecules that target specific tissues, organs, or cells within the human body. Radioisotopes emitting gamma rays are useful for diagnostic imaging where the radiation escapes the body. These rays are detected by a specific device, which is usually single-photon emission computed tomography (SPECT)/ positron emission tomography (PET) cameras.
The factors that are driving growth of the market are rising prevalence of chronic diseases, suitability of alpha radioimmunotherapy in targeted cancer treatment, and advancements in nuclear imaging techniques.
Various companies have made organic growth strategies in the Radiopharmaceuticals Market. Some of the activities undertaken by the company, which have promoted its growth are, launches, enhancements and expansion & relocation activities. Companies such as Lantheus Medical Imaging, Inc., Bracco Imaging S.p.A, Advanced Accelerator Applications amongst others are some of the companies that have been implementing various organic strategies that have helped the growth of the company.
North America dominates the global radiopharmaceuticals market due to factors such as technological advancement, increasing product launches, well-developed healthcare facility centres equipped with modern-age equipment and instruments.
The diagnostic nuclear medicine segment is growing at the highest CAGR owing to availability of diagnostic devices and ease offered by these devices for diagnosis of various disorders. Also, nuclear medicine provides better diagnostic information about the functioning of a specific organ, as it uses radiation.
Asia Pacific is expected to be the fastest growing region in the radiopharmaceuticals market. The growth of the market in this region is primarily due to prevalence of stroke and other neurological disorders along with the presence of supportive government initiatives and research in the field of radiopharmaceuticals.
The List of Companies - Radiopharmaceuticals Market
- Cardinal Health
- GE Healthcare
- Curium
- Lantheus Medical Imaging
- Bayer AG
- Bracco Imaging
- Eczacýbaþý-Monrol Nuclear Products
- Nordion
- Advanced Accelerator Applications
- NTP Radioisotopes
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Aug 2021
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Aug 2021
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Aug 2021
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Aug 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Aug 2021
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)